Modeling Treatment Response in Tuberculosis Early Bactericidal Activity Trials
CPT: Pharmacometrics & Systems Pharmacology · 2026-08 · 15 (8)
DOI: 10.1002/psp4.70311 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 07.08.2026. Verfasst von Mairi C W McClean und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany. Hauptthemen laut MEDLINE: Antitubercular Agents, Mycobacterium tuberculosis, Models, Biological, Tuberculosis. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European and Developing Countries Clinical Trials Partnership (EDCTP), German Ministry of Education and Research (BMBF), German Center for Infection Research (DZIF).
Abstract (Originalsprache)
Culture‐based monitoring of bacterial load is slow and susceptible to missing data, contributing to the length and cost of TB clinical trials. Non‐culture‐based alternatives, like the Tuberculosis Molecular Load Bacterial Assay (TB‐MBLA), could represent a solution. Our objectives were to evaluate TB‐MBLA as a biomarker in early bactericidal activity (EBA) studies and explore whether combining biomarkers with joint modeling could provide insight into underlying biological processes. We generated TB‐MBLA (LifeArc) data from sputum samples from all 78 patients from the PanACEA BTZ‐043 Phase Ib/IIa trial and derived a summary measure of the joint distribution of the three TB‐MBLA, colony forming units (CFU), and time‐to‐positivity (TTP) biomarkers as the first principal component derived from a probabilistic principal component analysis (pPCA). With TB‐MBLA marker and the principal component 1 (PC1) values, we reevaluated the original stage IIa dose–response and stages Ib/IIa pharmacokinetics—pharmacodynamics (PK‐PD) exposure‐response analyses, applying linear and non‐linear mixed models, respectively. For TB‐MBLA, we could not detect an exposure‐response effect in the PK‐PD analysis, in contrast with CFU and TTP. When combining biomarkers, we observed a significant but less pronounced E max exposure–response between days 0–3 compared with CFU and TTP alone. We also successfully applied pPCA as a modeling framework and show evidence that combining CFU and TTP in a joint latent component can improve detection of treatment effects compared with either biomarker alone. In this study, we present novel EBA data for the first‐in‐class antimycobacterial compound BTZ‐043 and contextualize the value of emerging bacteriological markers within the EBA trial framework. Trial Registration: ClinicalTrials.gov identifier: NCT04044001
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany.
- Institute of AI for Health, Helmholtz Center Munich-German Research Center for Environmental Health, Neuherberg, Germany.
- Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), Pettenkofer School of Public Health, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany.
- Helmholtz Pioneer Campus, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.
- Department of Pharmacy, Pharmacology, and Toxicology, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands.
- German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany.
ORCID-Profile: Mairi C W McClean, Simon E Koele, Julia Dreisbach, Fred Njeleka, Daniel Mapamba, Bariki Mtafya, Patrick P J Phillips, Veronique R De Jager, Rodney Dawson, Kim Narunsky, Andreas H Diacon, Elin M Svensson, Norbert Heinrich, Francesco Paolo Casale, Michael Hoelscher
Förderung
- European and Developing Countries Clinical Trials Partnership (EDCTP)
- German Ministry of Education and Research (BMBF)
- German Center for Infection Research (DZIF)
- Bavarian Ministry to their institutions
- LigaChem Biosciences
- Janssen Pharmaceuticals
- TB Alliance
- Free State of Bavaria's Hightech Agenda
Zitieren
APA
McClean, M. C. W., Koele, S. E., Dreisbach, J., Mirold-Mei, S., Njeleka, F., Mapamba, D., Mtafya, B., Phillips, P. P. J., De Jager, V. R., Dawson, R., Narunsky, K., Diacon, A. H., Svensson, E. M., Heinrich, N., Casale, F. P., & Hoelscher, M. (2026). Modeling Treatment Response in Tuberculosis Early Bactericidal Activity Trials. CPT: Pharmacometrics & Systems Pharmacology, 15(8). https://doi.org/10.1002/psp4.70311
Vancouver
McClean MCW, Koele SE, Dreisbach J, Mirold-Mei S, Njeleka F, Mapamba D, et al. Modeling Treatment Response in Tuberculosis Early Bactericidal Activity Trials. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(8). doi:10.1002/psp4.70311
BibTeX
@article{McClean2026,
author = {McClean, Mairi C W and Koele, Simon E and Dreisbach, Julia and Mirold-Mei, Susanne and Njeleka, Fred and Mapamba, Daniel and Mtafya, Bariki and Phillips, Patrick P J and De Jager, Veronique R and Dawson, Rodney and Narunsky, Kim and Diacon, Andreas H and Svensson, Elin M and Heinrich, Norbert and Casale, Francesco Paolo and Hoelscher, Michael},
title = {Modeling Treatment Response in Tuberculosis Early Bactericidal Activity Trials},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2026},
volume = {15},
number = {8},
doi = {10.1002/psp4.70311}
}
EUVIMED